中港照相(01123.HK)全年實現純利3360萬元 末期息1港仙
格隆匯6月25日丨中港照相(01123.HK)發佈公吿,截至2021年3月31日止年度,收益增加4.1%至港幣9.17億元;公司股東應占淨利潤為港幣3360萬元,上年同期則為淨虧損港幣2910萬元;每股盈利為2.84港仙;董事會建議派付末期股息每股普通股1港仙。
公吿表示,集團該年度的收益較去年增加4.1%,並錄得收益總額港幣9.17億元。此為多項內外因素交織下所致。儘管集團攝影分類的銷售額因旅遊限制及經濟轉差而大幅下跌,但此跌幅大部分被消費電子產品及家用電器分類的銷售額升幅抵銷。具體而言,集團電視及音響器材等優質家居娛樂產品的需求飆升,因港人留待家中的時間比以往長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.